International audienceOBJECTIVES: The contribution of the AT2 and AT4 angiotensin receptors to the protective role of the AT1 receptor blocker candesartan in acute ischemic stroke was investigated. METHODS: Embolic stroke was induced by injection of calibrated microspheres (50 microm) in the right internal carotid in Sprague-Dawley rats. RESULTS: Inhibition of production of endogenous angiotensins by pretreatment for 24 h with lisinopril significantly increased mortality and infarct volume, whereas candesartan for 24 h reduced blood pressure to the same extent but had no deleterious effect. A more sustained pretreatment with candesartan for 5 days significantly decreased mortality, neurological deficit and infarct size. The AT2 receptor ant...
One of common pathophysiological states associated with central nervous system is chronic cerebral h...
Background and aim: Angiotensin II acts through two major receptors: AT1-R and AT2-R. It is known th...
Background: In this study, the neuroprotective effect of a novel nonpeptide AT2R agonist, C21, wa...
Objectives: The contribution of the AT2 and AT4 angiotensin receptors to the protective role of the ...
Pre-treatment with candesartan protects from cerebral ischaemia Takeshi Ito, Yasuaki Nishimura, Juan...
Background: Stroke is the third leading cause of invalidism and death in industrialized countries. T...
OBJECTIVE: Pre-treatment with angiotensin receptor blockers is known to improve neurological outcome...
The effects of AT1 receptor blocker, telmisartan, and the ACE inhibitor, ramipril, were tested head-...
The effects of AT1 receptor blocker, telmisartan, and the ACE inhibitor, ramipril, were tested head-...
Stroke is a leading cause of adult disability worldwide. Improving stroke outcome requires an orches...
Background: In this study, the neuroprotective effect of a novel nonpeptide AT2R agonist, C21, was e...
Objective: Pre-treatment with angiotensin receptor blockers is known to improve neurological outcome...
Background: In this study, the neuroprotective effect of a novel nonpeptide AT2R agonist, C21, was e...
Background: In this study, the neuroprotective effect of a novel nonpeptide AT2R agonist, C21, was e...
Background: In this study, the neuroprotective effect of a novel nonpeptide AT2R agonist, C21, was e...
One of common pathophysiological states associated with central nervous system is chronic cerebral h...
Background and aim: Angiotensin II acts through two major receptors: AT1-R and AT2-R. It is known th...
Background: In this study, the neuroprotective effect of a novel nonpeptide AT2R agonist, C21, wa...
Objectives: The contribution of the AT2 and AT4 angiotensin receptors to the protective role of the ...
Pre-treatment with candesartan protects from cerebral ischaemia Takeshi Ito, Yasuaki Nishimura, Juan...
Background: Stroke is the third leading cause of invalidism and death in industrialized countries. T...
OBJECTIVE: Pre-treatment with angiotensin receptor blockers is known to improve neurological outcome...
The effects of AT1 receptor blocker, telmisartan, and the ACE inhibitor, ramipril, were tested head-...
The effects of AT1 receptor blocker, telmisartan, and the ACE inhibitor, ramipril, were tested head-...
Stroke is a leading cause of adult disability worldwide. Improving stroke outcome requires an orches...
Background: In this study, the neuroprotective effect of a novel nonpeptide AT2R agonist, C21, was e...
Objective: Pre-treatment with angiotensin receptor blockers is known to improve neurological outcome...
Background: In this study, the neuroprotective effect of a novel nonpeptide AT2R agonist, C21, was e...
Background: In this study, the neuroprotective effect of a novel nonpeptide AT2R agonist, C21, was e...
Background: In this study, the neuroprotective effect of a novel nonpeptide AT2R agonist, C21, was e...
One of common pathophysiological states associated with central nervous system is chronic cerebral h...
Background and aim: Angiotensin II acts through two major receptors: AT1-R and AT2-R. It is known th...
Background: In this study, the neuroprotective effect of a novel nonpeptide AT2R agonist, C21, wa...